Contact
searchSearch
HMP Global

Non-Small Cell Lung Cancer Topic Center

NSCLC, Oncology Coverage, Oncology Access
Videos
What PALOMA-3 Signals for Coverage, Access, and Care Delivery in NSCLC
02/02/2026
Narjust Florez, MD
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust...
02/02/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
Optimizing NSCLC Care Through Extended Dosing and Alternative Formulations
01/27/2026
Corrine Stahura, PharmD, BCOP
Corrine Stahura, PharmD, BCOP, discusses how extended dosing intervals and subcutaneous formulations in non–small cell lung cancer are improving patient convenience, reducing infusion center burden, and enhancing operational efficiency while...
Corrine Stahura, PharmD, BCOP, discusses how extended dosing intervals and subcutaneous formulations in non–small cell lung cancer are improving patient convenience, reducing infusion center burden, and enhancing operational efficiency while...
Corrine Stahura, PharmD, BCOP,...
01/27/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
Treatment Paradigms in NSCLC: Chemo-Based vs Non-Chemo Regimens
01/27/2026
Rajat Thawani, MD
Dr Rajat Thawani discusses how biomarker-driven strategies, emerging immunotherapies, and novel delivery approaches are rapidly redefining first-line non-small cell lung cancer (NSCLC) treatment—shifting care beyond traditional chemotherapy...
Dr Rajat Thawani discusses how biomarker-driven strategies, emerging immunotherapies, and novel delivery approaches are rapidly redefining first-line non-small cell lung cancer (NSCLC) treatment—shifting care beyond traditional chemotherapy...
Dr Rajat Thawani discusses how...
01/27/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
Evaluating Total Cost Considerations in Non–Small Cell Lung Cancer Care
01/27/2026
Estelamari Rodriguez, MD, MPH
As new subcutaneous and targeted therapies enter the NSCLC landscape, the true cost of care extends far beyond drug price alone. In this interview, Estelamari Rodriguez, MD, MPH, a thoracic oncologist at Sylvester Comprehensive Cancer Center,...
As new subcutaneous and targeted therapies enter the NSCLC landscape, the true cost of care extends far beyond drug price alone. In this interview, Estelamari Rodriguez, MD, MPH, a thoracic oncologist at Sylvester Comprehensive Cancer Center,...
As new subcutaneous and targeted...
01/27/2026
First Report Managed Care
News
Stage and Access Predict Outcomes in Early Onset NSCLC
11/10/2025
Juliet Gallagher
Early-onset non–small cell lung cancer (NSCLC) remains understudied. A retrospective cohort analysis published in JAMA Network Open used SEER data (2010–2021) to evaluate which demographic, clinical, and socioeconomic factors are associated...
Early-onset non–small cell lung cancer (NSCLC) remains understudied. A retrospective cohort analysis published in JAMA Network Open used SEER data (2010–2021) to evaluate which demographic, clinical, and socioeconomic factors are associated...
Early-onset non–small cell lung...
11/10/2025
First Report Managed Care
Hsu Headshot
Videos
Understanding the Changing Landscape of NSCLC in the US
07/11/2025
Melinda Hsu, MD
Dr. Melinda Hsu, thoracic oncologist and cancer survivorship director at UH Simon Cancer Center, shares insights on the evolving landscape of non–small cell lung cancer—highlighting challenges in early detection, treatment tolerability, and...
Dr. Melinda Hsu, thoracic oncologist and cancer survivorship director at UH Simon Cancer Center, shares insights on the evolving landscape of non–small cell lung cancer—highlighting challenges in early detection, treatment tolerability, and...
Dr. Melinda Hsu, thoracic...
07/11/2025
First Report Managed Care
Rodriguez Headshot
Videos
Addressing Disparities in NSCLC With Timely Biomarker Testing and Navigation Tools
07/11/2025
Estelamari Rodriguez, MD, MPH
Dr. Estelamari Rodriguez, clinical research lead for thoracic oncology at the University of Miami Sylvester Cancer Center, explores how early biomarker testing, equitable access, artificial intelligence (AI)-driven data integration, and...
Dr. Estelamari Rodriguez, clinical research lead for thoracic oncology at the University of Miami Sylvester Cancer Center, explores how early biomarker testing, equitable access, artificial intelligence (AI)-driven data integration, and...
Dr. Estelamari Rodriguez,...
07/11/2025
First Report Managed Care
Thawani
Videos
Advancing NSCLC Care: Targeted Strategies, Real-World Barriers, and the Future of Treatment Pathways
07/11/2025
Rajat Thawani, MD
Dr. Rajat Thawani, a thoracic oncologist at OHSU Knight Cancer Institute, discusses groundbreaking advances in lung cancer treatment—highlighting the promise of antibody-drug conjugates (ADCs), the critical role of biomarker testing, and the...
Dr. Rajat Thawani, a thoracic oncologist at OHSU Knight Cancer Institute, discusses groundbreaking advances in lung cancer treatment—highlighting the promise of antibody-drug conjugates (ADCs), the critical role of biomarker testing, and the...
Dr. Rajat Thawani, a thoracic...
07/11/2025
First Report Managed Care
News
Medicaid Expansion Linked to Improved Access to Local Therapy for Early-Stage Lung Cancer
06/09/2025
Juliet Gallagher
A recent retrospective study using the National Cancer Database suggests that Medicaid expansion under the Affordable Care Act (ACA) may improve access to local therapy—surgery or stereotactic body radiation therapy (SBRT)—for patients with...
A recent retrospective study using the National Cancer Database suggests that Medicaid expansion under the Affordable Care Act (ACA) may improve access to local therapy—surgery or stereotactic body radiation therapy (SBRT)—for patients with...
A recent retrospective study...
06/09/2025
First Report Managed Care
News
Immune Checkpoint Inhibitor Regimens Drive Higher Costs in First-Line NSCLC Treatment
05/13/2025
Lisa Kuhns, PhD, MD
First-line (1L) treatment with immune checkpoint inhibitors (ICIs), particularly in combination with chemotherapy, is the most frequently used and costliest systemic therapy for metastatic non-small cell lung cancer (NSCLC) patients without...
First-line (1L) treatment with immune checkpoint inhibitors (ICIs), particularly in combination with chemotherapy, is the most frequently used and costliest systemic therapy for metastatic non-small cell lung cancer (NSCLC) patients without...
First-line (1L) treatment with...
05/13/2025
First Report Managed Care
Interactive Features
Poll Quiz

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use